ReviewInternational journal of preventive medicine2026
Outcomes of GnRH Agonist Therapy in Boys with Central Precocious Puberty: A Systematic Review of Final Height and Long-Term Health Effects.
Review in International journal of preventive medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Central precocious puberty (CPP) in boys can result in accelerated growth, early epiphyseal fusion, and reduced adult height. Gonadotropin-releasing hormone agonists (GnRHa) are commonly used to delay pubertal progression and preserve growth potential. However, data on their long-term effects on final height, bone health, and body mass index (BMI) remain limited. This systematic review aimed to evaluate the outcomes of GnRH agonist therapy in boys with CPP, focusing on final height and reported side effects. Methods: A systematic literature search was conducted across five databases for studies published from 2000 to 2023. Studies included boys with idiopathic or non-idiopathic CPP treated with GnRH agonists, reporting outcomes related to final height, BMI, or bone health. Data were synthesized qualitatively. Results: GnRH agonist therapy significantly improved final height outcomes, particularly in idiopathic CPP cases, with boys often achieving heights near or exceeding their genetic target. Non-idiopathic CPP cases showed more variable results. Bone health assessments were limited, and long-term impacts on bone mineral density (BMD) remain unclear. Transient increases in BMI were observed during therapy, with no substantial long-term risk of obesity. Conclusions: In general, no serious side effects were reported. GnRH agonist therapy is effective in improving final height in boys with CPP, especially in idiopathic cases. However, more research is needed to understand its long-term effects on bone health and metabolic outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.